专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100183714A1 GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM COMPRISING N-(2-(2- PHTHALIMIDOETHOXY)-ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK-423) 审中-公开
标题翻译：包含N-（2-（2-羟基乙酰氧基） - 乙酰基）-L-氨基-D-谷氨酰胺（LK-423）的胃肠药物剂型
公开(公告)号：US20100183714A1
公开(公告)日：2010-07-22
申请号：US10599289
申请日：2005-03-24
申请人： Marija Bogataj , Ales Mrhar , Anton Lavric , Manica Cerne , Doris Tibaut , Anton Stalc , Uros Urleb , Tatjana Mateovic , Greta Cof , Janez Kerc , Rok Dreu , Fumio Yoneda , Shizuko Muraoka
发明人： Marija Bogataj , Ales Mrhar , Anton Lavric , Manica Cerne , Doris Tibaut , Anton Stalc , Uros Urleb , Tatjana Mateovic , Greta Cof , Janez Kerc , Rok Dreu , Fumio Yoneda , Shizuko Muraoka
IPC分类号： A61K9/36 , C07D209/48 , A61K9/14 , A61K38/05 , A61K9/16 , A61K9/50 , A61K9/28 , A61K9/48 , A61K9/32 , A61P1/04 , A61P1/00 , A61P29/00
CPC分类号： A61K9/5073 , A61K9/2095
摘要： The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.
摘要翻译：本发明涉及能够将活性物质受控和/或定向递送到人或动物的所选择的胃肠道区域的药物剂型。药物剂型优选包含活性物质N-（2（2-苯二酰亚氨基乙氧基） - 乙酰基）-L-丙氨酰-D-谷氨酸（命名为LK 423）。公开了通过使用本发明的药物剂型治疗人和/或动物的胃肠道的慢性炎性疾病的方法。

2. 发明申请

US20080206322A1 Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin 审中-公开
标题翻译：药物多微粒复合物离子包含霉酚酸或肌醇酸钠和组合组合物与雷帕霉素
公开(公告)号：US20080206322A1
公开(公告)日：2008-08-28
申请号：US11573647
申请日：2005-08-29
申请人： Dieter Becker , Jutta Beyer , Janez Kerc , Andrea Kramer , Nicoletta Loggia , Chirstian-Peter Luftensteiner , Jorg Ogorka
发明人： Dieter Becker , Jutta Beyer , Janez Kerc , Andrea Kramer , Nicoletta Loggia , Chirstian-Peter Luftensteiner , Jorg Ogorka
IPC分类号： A61K9/52 , C07D307/77 , A61K9/14 , A61K31/4353 , A61P37/06 , A61K31/343 , A61K9/22
CPC分类号： A61K9/1652 , A61K9/2054 , A61K9/2866 , A61K9/5026 , A61K9/5078 , A61K31/365 , A61K31/436 , A61K2300/00
摘要： The present invention relates to a novel composition, e.g. of mycophenolic acid, a salt or a prodrug thereof, in a modified release form.
摘要翻译：本发明涉及一种新的组合物，例如，的霉酚酸，其盐或前药，以改性释放形式存在。

3. 发明申请

US20060121106A1 Therapeutic system comprising amoxicillin and clavulanic acid 审中-公开
标题翻译：包含阿莫西林和克拉维酸的治疗系统
公开(公告)号：US20060121106A1
公开(公告)日：2006-06-08
申请号：US10545111
申请日：2004-02-20
申请人： Janez Kerc , Jerneja Opara , Maja Jenko Osel
发明人： Janez Kerc , Jerneja Opara , Maja Jenko Osel
IPC分类号： A61K31/43 , A61K31/407 , A61K9/48
CPC分类号： A61K9/0065 , A61K9/2054 , A61K9/2866 , A61K9/4808 , A61K9/4866 , A61K9/4891 , A61K9/5084 , A61K45/06
摘要： The present invention relates to a novel therapeutic system suitable for one or twice daily administration of amoxicillin and clavulanic acid. One part of the dosage is provided by at least one immediate release amoxicillin/clavulanic acid pharmaceutical composition, and the other part of the dosage is provided by at least one delayed and sustained release gastroretentive amoxicillin pharmaceutical composition.
摘要翻译：本发明涉及适用于每天一次或两次给予阿莫西林和克拉维酸的新型治疗系统。剂量的一部分由至少一种立即释放阿莫西林/克拉维酸药物组合物提供，另一部分剂量由至少一种延迟释放的胃滞留阿莫西林药物组合物提供。

4. 发明授权

US09149460B2 Coated particles and pharmaceutical dosage forms 有权
标题翻译：涂层颗粒和药物剂型
公开(公告)号：US09149460B2
公开(公告)日：2015-10-06
申请号：US11862470
申请日：2007-09-27
申请人： Vlasta Humar , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
发明人： Vlasta Humar , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
IPC分类号： A61K9/24 , A61K31/225 , A61K31/40 , A61K9/20 , A61K9/28
CPC分类号： A61K9/5047 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/40
摘要： The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.
摘要翻译：本发明涉及包含对环境影响敏感的活性物质的包衣颗粒和药物剂型。本发明的涂层提供活性物质对于环境影响的稳定性和保护，特别是通过涂覆从氧化和/或环境湿度。

5. 发明申请

US20080242725A1 Pharmaceutical Composition 审中-公开
标题翻译：药物组成
公开(公告)号：US20080242725A1
公开(公告)日：2008-10-02
申请号：US10590780
申请日：2005-02-28
申请人： Janez Kerc , Peter Svete , Zdenka Jerala-Strukelj , Vlasta Humar , Rok Grahek , Breda Husu-Kovacevic
发明人： Janez Kerc , Peter Svete , Zdenka Jerala-Strukelj , Vlasta Humar , Rok Grahek , Breda Husu-Kovacevic
IPC分类号： A61K31/225 , A61K47/26 , A61P9/10
CPC分类号： A61K9/1652 , A61K31/4184 , A61K31/695 , C07C67/62 , C07C2602/28 , C07C69/33
摘要： Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions.
摘要翻译：包含易于转化为交替多晶型形式的活性药物成分的多晶型物的稳定化药物组合物是通过湿法制粒方法制备的，其中控制活性成分，填充剂和制粒液体的比例以避免多晶型相互转化。

6. 发明申请

US20080138429A1 Coated Particles and Pharmaceutical Dosage Forms 有权
标题翻译：涂层颗粒和药物剂型
公开(公告)号：US20080138429A1
公开(公告)日：2008-06-12
申请号：US11862470
申请日：2007-09-27
申请人： Vlasta HUMAR , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
发明人： Vlasta HUMAR , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
IPC分类号： A61K9/50 , A61K31/401
CPC分类号： A61K9/5047 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/40
摘要： The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.
摘要翻译：本发明涉及包含对环境影响敏感的活性物质的包衣颗粒和药物剂型。本发明的涂层提供活性物质对于环境影响的稳定性和保护，特别是通过涂覆从氧化和/或环境湿度。

7. 发明申请

US20120135976A1 PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING EZETIMIBE 有权
标题翻译：制备包含EZETIMIBE的药物组合物的方法
公开(公告)号：US20120135976A1
公开(公告)日：2012-05-31
申请号：US13147956
申请日：2010-02-05
申请人： Janez Kerc , Miha Homar , Polona Jurkovic
发明人： Janez Kerc , Miha Homar , Polona Jurkovic
IPC分类号： A61K31/397 , A61P7/00
CPC分类号： A61K9/145 , A61K9/2018 , A61K9/2095
摘要： The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing ezetimibe, comprising the steps of: a) providing a composition comprising ezetimibe, b) sieving a composition comprising a composition of step (a), c) shear mixing of the composition after step (b), preferably the mixing of the composition is carried out by high shear mixing, d) formulation into a dosage form. The present invention also relates to dosage forms containing ezetimibe and ezetimibe and simvastatin, which have been prepared according to the process according to the invention.
摘要翻译：本发明属于制药工业领域，涉及制备含有依泽替米贝的剂型的方法，该方法包括以下步骤：a）提供包含依泽麦布的组合物，b）筛分包含步骤（a），c ）组合物在步骤（b）之后的剪切混合，优选组合物的混合通过高剪切混合进行，d）配制成剂型。本发明还涉及根据本发明的方法制备的依泽替米贝，依泽替米贝和辛伐他汀的剂型。

8. 发明申请

US20110068497A1 PREPARATION OF NANOPARTICLES BY USING A VIBRATING NOZZLE DEVICE 审中-公开
标题翻译：使用振动喷嘴装置制备纳米颗粒
公开(公告)号：US20110068497A1
公开(公告)日：2011-03-24
申请号：US12865479
申请日：2009-01-29
申请人： Pegi Ahlin Grabnar , Alenka Zvonar , Julijana Kristl , Polona Jurkovic , Janez Kerc
发明人： Pegi Ahlin Grabnar , Alenka Zvonar , Julijana Kristl , Polona Jurkovic , Janez Kerc
IPC分类号： B29B9/12 , B82Y5/00
CPC分类号： A61K9/5153 , A61K9/1647 , A61K9/1694 , A61K9/5192 , B01J13/04
摘要： A method for preparing nanoparticles is provided, which comprises the steps of dissolving a polymer and, optionally, at least one additional ingredient, in an organic solvent, passing the solution through a vibrating nozzle and dropping the solution through the electrical field into an aqueous solution, which is stirred, such that nanoparticles are formed by the rapid diffusion of the solvent.
摘要翻译：提供了一种制备纳米颗粒的方法，其包括将聚合物和任选的至少一种另外的成分溶解在有机溶剂中，使溶液通过振动喷嘴并将溶液通过电场滴入水溶液中的步骤，其被搅拌，使得通过溶剂的快速扩散形成纳米颗粒。

9. 发明申请

US20060093680A1 Coated particles and pharmaceutical dosage forms 审中-公开
公开(公告)号：US20060093680A1
公开(公告)日：2006-05-04
申请号：US10544920
申请日：2004-02-11
申请人： Vlasta Humar , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
发明人： Vlasta Humar , Mateja Burjak , Rok Grahek , Mateja Salobir , Janez Kerc , Klemen Kocevar
IPC分类号： A61K31/401 , A61K9/50 , A61K9/16
CPC分类号： A61K9/5047 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/40
摘要： The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.

10. 发明授权

US06806290B2 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same 失效
标题翻译：稳定的药学有效组合物和包含其的药物制剂
公开(公告)号：US06806290B2
公开(公告)日：2004-10-19
申请号：US10298187
申请日：2002-11-15
申请人： Zlatko Pflaum , Janez Kerc
发明人： Zlatko Pflaum , Janez Kerc
IPC分类号： A61K31225
CPC分类号： A61K31/366 , A61K31/401
摘要： Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.
摘要翻译：洛伐他汀，普伐他汀，辛伐他汀，美伐他汀，阿托伐他汀及其衍生物和类似物被称为HMG-CoA还原酶抑制剂，并用作抗高胆固醇血症药。它们中的大多数是通过使用被鉴定为曲霉属，红曲霉，诺卡氏菌属，无性系，毛霉属或青霉属的物种的不同物种的微生物进行发酵的，一些是通过使用化学合成方法处理发酵产物而得到的，或者它们是化学合成产物。上述活性物质可能被环境因素不稳定，它们的降解也可以通过与其它药物成分例如填料，粘合剂，润滑剂，助流剂和崩解剂的相互作用而加速，因此药物成分和药物制备方法应精心选择配方以避免上述不良的相互作用和反应。本发明涉及通过用缓冲物质或碱化物质形成均匀组合物来稳定的HMG-CoA还原酶抑制剂。该均匀组合物适合用作用于治疗高胆固醇血症和高脂血症的药物制剂中的活性物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式